Differential Biochemical Markers Identified in Inflammatory Processed Synovial Fluid
By LabMedica International staff writers Posted on 06 Oct 2021 |

Image: The AU5800 Clinical Chemistry Analyzer is an automated chemistry analyzer that measures many different chemical analytes (Photo courtesy of Beckman Coulter)
Joint infections with a non-specific presentation are difficult to diagnose, mainly due to the absence of specific clinical signs and symptoms, relative lack of accurate laboratory tests, low virulence due to previous treatment, and biofilm ability of the pathogens.
This difficulty is especially true for patients treated with non-targeted antibiotics, including patients with implanted joint replacements. New biochemical markers are being sought to help quickly determine the extent of the inflammatory process taking place in the joint cavity in routine biochemical practice, either due to its increased concentration in synovial fluid (SF) or directly in serum/plasma.
Clinical Biochemists and their colleagues at the University of Ostrava (Ostrava, Czech Republic) sought to identify biochemical markers in Synovial Fluid (SF) that can predict susceptibility to ongoing inflammatory processes in the joint cavity. Ninety-two consecutive patients were divided into four SF groups based on clustering analysis: non-inflammatory SF (73%), inflammatory-non-pyogenic (12%), inflammatory-pyogenic (10%), or hemorrhagic (5%).
The team measured and compared the levels of the following biochemical markers in SF: glucose, lactate, total protein, uric acid, C-Reactive Protein (CRP), Leukocyte Count (WBC), Mononuclear (MNP), Polymorphonuclear (PMN), Interleukin (IL)-1 beta, IL6, Procalcitonin, Presepsin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Human Neutrophil Defensin 1-3 (HNP1-3), Cartilage Oligomeric Matrix Protein, Lactoferrin (HLF2), Polymorphonuclear Elastase (PMNE), Matrix Metalloproteinase (MMP)-1, and MMP-3. The concentrations of the biochemical biomarkers were determined on an AU 5800 automated analyzer (Beckman Coulter, Brea, CA, USA). They analyzed hematological parameters, relative and absolute numbers of leukocytes (WBC), and (MNP) and PMN leukocyte counts on a XN-9000 Automated in Body Fluid mode (Sysmex, Kobe, Japan).
The scientists reported that a significant difference between WBC, PMN, MNP, CRP, IL-1β, IL-6, HNP1-3, HLF2, PMNE, and individual groups of SF type. They also found a significant correlation between WBC and PMN, MNP, and CRP; PMN and HNP1-3 and PMNE; IL-6 and PMNE; IL-1β and NGAL, HLF2, and PMNE; HNP1-3 and NGAL, HLF2, and PMNE; NGAL and HLF2 and PMNE; and HLF2 and PMNE concentrations in all SF groups, between WBC and MNP; IL-1β and NGAL and MMP-3; HNP1-3 and PMNE; and NGAL and HLF2 concentrations in the non-inflammatory SF group, and between PMN and MNP in the inflammatory-non-pyogenic and inflammatory-pyogenic SF groups. PMN, MNP, WBC, CRP, and HNP1-3 in SF predicted the inflammatory processes with excellent diagnostic performance.
The authors concluded that SF biomarkers WBC, PMN, MNP CRP, HNP1-3, IL-1, IL-6, PMNE, and HLF2 allow the classification of new patients into the relevant SF group with an accuracy of 94.4%. In addition, WBC, PMN, MNP, CRP, and HNP1-3 provide excellent diagnostic sensitivity and specificity for the diagnosis of infection, despite the study including a limited number of patients with pyogenic and non-pyogenic inflammation. The study was originally published on line on March 15, 2021 in the Journal of Clinical Chemistry and Laboratory Medicine.
Related Links:
University of Ostrava
Beckman Coulter
Sysmex
This difficulty is especially true for patients treated with non-targeted antibiotics, including patients with implanted joint replacements. New biochemical markers are being sought to help quickly determine the extent of the inflammatory process taking place in the joint cavity in routine biochemical practice, either due to its increased concentration in synovial fluid (SF) or directly in serum/plasma.
Clinical Biochemists and their colleagues at the University of Ostrava (Ostrava, Czech Republic) sought to identify biochemical markers in Synovial Fluid (SF) that can predict susceptibility to ongoing inflammatory processes in the joint cavity. Ninety-two consecutive patients were divided into four SF groups based on clustering analysis: non-inflammatory SF (73%), inflammatory-non-pyogenic (12%), inflammatory-pyogenic (10%), or hemorrhagic (5%).
The team measured and compared the levels of the following biochemical markers in SF: glucose, lactate, total protein, uric acid, C-Reactive Protein (CRP), Leukocyte Count (WBC), Mononuclear (MNP), Polymorphonuclear (PMN), Interleukin (IL)-1 beta, IL6, Procalcitonin, Presepsin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Human Neutrophil Defensin 1-3 (HNP1-3), Cartilage Oligomeric Matrix Protein, Lactoferrin (HLF2), Polymorphonuclear Elastase (PMNE), Matrix Metalloproteinase (MMP)-1, and MMP-3. The concentrations of the biochemical biomarkers were determined on an AU 5800 automated analyzer (Beckman Coulter, Brea, CA, USA). They analyzed hematological parameters, relative and absolute numbers of leukocytes (WBC), and (MNP) and PMN leukocyte counts on a XN-9000 Automated in Body Fluid mode (Sysmex, Kobe, Japan).
The scientists reported that a significant difference between WBC, PMN, MNP, CRP, IL-1β, IL-6, HNP1-3, HLF2, PMNE, and individual groups of SF type. They also found a significant correlation between WBC and PMN, MNP, and CRP; PMN and HNP1-3 and PMNE; IL-6 and PMNE; IL-1β and NGAL, HLF2, and PMNE; HNP1-3 and NGAL, HLF2, and PMNE; NGAL and HLF2 and PMNE; and HLF2 and PMNE concentrations in all SF groups, between WBC and MNP; IL-1β and NGAL and MMP-3; HNP1-3 and PMNE; and NGAL and HLF2 concentrations in the non-inflammatory SF group, and between PMN and MNP in the inflammatory-non-pyogenic and inflammatory-pyogenic SF groups. PMN, MNP, WBC, CRP, and HNP1-3 in SF predicted the inflammatory processes with excellent diagnostic performance.
The authors concluded that SF biomarkers WBC, PMN, MNP CRP, HNP1-3, IL-1, IL-6, PMNE, and HLF2 allow the classification of new patients into the relevant SF group with an accuracy of 94.4%. In addition, WBC, PMN, MNP, CRP, and HNP1-3 provide excellent diagnostic sensitivity and specificity for the diagnosis of infection, despite the study including a limited number of patients with pyogenic and non-pyogenic inflammation. The study was originally published on line on March 15, 2021 in the Journal of Clinical Chemistry and Laboratory Medicine.
Related Links:
University of Ostrava
Beckman Coulter
Sysmex
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more